Tixagevimab-Cilgavimab Treatment and Cardiovascular Events: Immortal Time Bias-Reference-Cited by-同舟云学术

Tixagevimab-Cilgavimab Treatment and Cardiovascular Events: Immortal Time Bias

Published:2023-02-17 Issue:11 Volume:76 Page:2044-2045
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Montastruc François¹²^ORCID,de Canecaude Claire¹²

Affiliation:

1. Department of Medical and Clinical Pharmacology, Faculty of Medicine, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital (CHU) , Toulouse , France

2. Centre d’Investigation Clinique 1436, Team PEPSS (Pharmacologie En Population cohorteS et biobanqueS), Toulouse University Hospital , Toulouse , France

Funder

French National Research Agency

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciad089/49548021/ciad089.pdf

Reference10 articles.

1. Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis against coronavirus disease 2019: a population-based propensity-matched cohort study;Birabaharan;Clin Infect Dis,2023

2. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of COVID-19;Levin;N Engl J Med,2022

3. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial;Montgomery;Lancet Respir Med,2022

4. Cardiac and vascular serious adverse events following tixagevimab–cilgavimab;Piszczek;Lancet Respir Med,2023

5. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimab for coronavirus disease 2019.;Montastruc;Clin Microbiol Infect

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Montastruc et al;Clinical Infectious Diseases;2023-02-21